Sun Xiaodan, Wang Shouhan, Gai Junda, Guan Jingqian, Li Ji, Li Yizhuo, Zhao Jinming, Zhao Chen, Fu Lin, Li Qingchang
Department of Pathology, College of Basic Medical Sciences, China Medical University, Shenyang, China.
Department of Hepatopancreatobiliary Surgery, Jilin Province Cancer Hospital, Changchun, China.
Front Oncol. 2019 Aug 13;9:754. doi: 10.3389/fonc.2019.00754. eCollection 2019.
Sirtuin 5 (SIRT5), a mitochondrial class III NAD-dependent deacetylase, plays controversial roles in tumorigenesis and chemoresistance. Accordingly, its role in ovarian cancer development and drug resistance is not fully understood. Here, we demonstrate that SIRT5 is increased in ovarian cancer tissues compared to its expression in normal tissues and this predicts a poor response to chemotherapy. SIRT5 levels were also found to be higher in cisplatin-resistant SKOV-3 and CAOV-3 ovarian cancer cells than in cisplatin-sensitive A2780 cells. Furthermore, this protein was revealed to facilitate ovarian cancer cell growth and cisplatin-resistance . Mechanistically, we show that SIRT5 contributes to cisplatin resistance in ovarian cancer by suppressing cisplatin-induced DNA damage in a reactive oxygen species (ROS)-dependent manner via regulation of the nuclear factor erythroid 2-related factor 2 (Nrf2)/heme oxygenase 1 (HO-1) pathway.
沉默调节蛋白5(SIRT5)是一种线粒体III类烟酰胺腺嘌呤二核苷酸(NAD)依赖性脱乙酰酶,在肿瘤发生和化疗耐药中发挥着具有争议性的作用。因此,其在卵巢癌发展和耐药中的作用尚未完全明确。在此,我们证明,与正常组织中的表达相比,SIRT5在卵巢癌组织中的表达增加,这预示着对化疗的反应较差。还发现,顺铂耐药的SKOV-3和CAOV-3卵巢癌细胞中的SIRT5水平高于顺铂敏感的A2780细胞。此外,该蛋白被证实可促进卵巢癌细胞生长和顺铂耐药。从机制上讲,我们发现SIRT5通过调节核因子红细胞2相关因子2(Nrf2)/血红素加氧酶1(HO-1)途径,以活性氧(ROS)依赖的方式抑制顺铂诱导的DNA损伤,从而导致卵巢癌的顺铂耐药。